MiMedx Group, Inc. (NASDAQ: MDXG) is headquartered in Marietta, Georgia, with 690 full-time employees. It is a biopharmaceutical company that uses human placental tissue allografts to develop and sell regenerative biologics and adopts a patent protection process. Used in various medical fields.
MiMedx Group (MDXG):
MiMedx Group uses its proprietary PURION process to process human placental tissue to produce allografts. The company’s proprietary processing method uses aseptic processing technology in addition to terminal sterilization.
MiMedx Group’s biomaterial platform technologies include AmnioFix and EpiFix, which are tissue technologies for processing human amniotic membrane derived from donated placental tissue for homologous applications; OrthoFlo, an allograft derived from amniotic fluid, for homologous Application; Physio, a bone graft material containing 100% bone tissue without a carrier; CollaFix, a technology platform derived from collagen fiber technology, designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissue to enhance Its repair ability.
In addition, MiMedx Group also provides EpiCord, an umbilical cord allograft, which provides a connective tissue matrix to replace or supplement damaged or insufficient skin tissue; AmnioCord, an umbilical cord allograft, provides for the healing process Protect the environment; and AmnioFill, a cell tissue matrix allograft that enhances healing.
MiMedx Group products are widely used in wound care, burns, surgery, plastic surgery, spine, sports medicine, ophthalmology and dentistry.
MiMedx Group sells its products through direct sales teams, independent distributors, third-party representatives in the United States, and independent international distributors.